vs

Side-by-side financial comparison of Calumet, Inc. (CLMT) and Steris (STE). Click either name above to swap in a different company.

Steris is the larger business by last-quarter revenue ($1.5B vs $1.0B, roughly 1.4× Calumet, Inc.). Steris runs the higher net margin — 12.9% vs -3.6%, a 16.5% gap on every dollar of revenue. Steris produced more free cash flow last quarter ($199.5M vs $103.8M).

Calumet, Inc. is a U.S.-headquartered specialty products firm that manufactures and distributes high-value hydrocarbon and specialty chemical products. Its offerings include specialty oils, lubricants, waxes, and renewable fuel solutions, serving industrial, consumer, and transportation segments across North America.

Steris plc is an American-Irish-based medical equipment company specializing in sterilization and surgical products for the US healthcare system. Steris is operationally headquartered in Mentor, Ohio, and has been legally registered in Dublin, Ireland, for tax purposes since 2018. Previously the company was registered in the United Kingdom from 2014 to 2018.

CLMT vs STE — Head-to-Head

Bigger by revenue
STE
STE
1.4× larger
STE
$1.5B
$1.0B
CLMT
Higher net margin
STE
STE
16.5% more per $
STE
12.9%
-3.6%
CLMT
More free cash flow
STE
STE
$95.7M more FCF
STE
$199.5M
$103.8M
CLMT

Income Statement — Q4 FY2025 vs Q3 FY2026

Metric
CLMT
CLMT
STE
STE
Revenue
$1.0B
$1.5B
Net Profit
$-37.3M
$192.9M
Gross Margin
-0.3%
43.8%
Operating Margin
-6.2%
18.3%
Net Margin
-3.6%
12.9%
Revenue YoY
9.2%
Net Profit YoY
11.2%
EPS (diluted)
$-0.43
$1.96

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CLMT
CLMT
STE
STE
Q4 25
$1.0B
$1.5B
Q3 25
$1.1B
$1.5B
Q2 25
$1.0B
$1.4B
Q1 25
$993.9M
$1.5B
Q4 24
$1.4B
Q3 24
$1.1B
$1.3B
Q2 24
$1.1B
$1.3B
Q1 24
$1.1B
Net Profit
CLMT
CLMT
STE
STE
Q4 25
$-37.3M
$192.9M
Q3 25
$313.4M
$191.9M
Q2 25
$-147.9M
$177.4M
Q1 25
$-162.0M
$145.7M
Q4 24
$173.5M
Q3 24
$-100.6M
$150.0M
Q2 24
$-39.1M
$145.4M
Q1 24
$-1.4M
Gross Margin
CLMT
CLMT
STE
STE
Q4 25
-0.3%
43.8%
Q3 25
34.7%
44.2%
Q2 25
-4.2%
45.1%
Q1 25
-8.2%
43.3%
Q4 24
44.5%
Q3 24
0.4%
43.6%
Q2 24
5.6%
44.7%
Q1 24
40.2%
Operating Margin
CLMT
CLMT
STE
STE
Q4 25
-6.2%
18.3%
Q3 25
30.0%
18.2%
Q2 25
-9.8%
17.7%
Q1 25
-4.9%
14.6%
Q4 24
17.9%
Q3 24
-5.2%
16.5%
Q2 24
0.5%
14.5%
Q1 24
22.0%
Net Margin
CLMT
CLMT
STE
STE
Q4 25
-3.6%
12.9%
Q3 25
29.1%
13.1%
Q2 25
-14.4%
12.8%
Q1 25
-16.3%
9.8%
Q4 24
12.7%
Q3 24
-9.1%
11.3%
Q2 24
-3.4%
11.4%
Q1 24
-0.1%
EPS (diluted)
CLMT
CLMT
STE
STE
Q4 25
$-0.43
$1.96
Q3 25
$3.61
$1.94
Q2 25
$-1.70
$1.79
Q1 25
$-1.87
$1.48
Q4 24
$1.75
Q3 24
$-1.18
$1.51
Q2 24
$-0.48
$1.46
Q1 24
$-0.02

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CLMT
CLMT
STE
STE
Cash + ST InvestmentsLiquidity on hand
$125.1M
$423.7M
Total DebtLower is stronger
$2.1B
$1.9B
Stockholders' EquityBook value
$-732.7M
$7.2B
Total Assets
$2.7B
$10.6B
Debt / EquityLower = less leverage
0.27×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CLMT
CLMT
STE
STE
Q4 25
$125.1M
$423.7M
Q3 25
$94.6M
$319.2M
Q2 25
$110.6M
$279.7M
Q1 25
$123.4M
$171.7M
Q4 24
$155.2M
Q3 24
$34.6M
$172.2M
Q2 24
$7.0M
$198.3M
Q1 24
$207.0M
Total Debt
CLMT
CLMT
STE
STE
Q4 25
$2.1B
$1.9B
Q3 25
$2.1B
$1.9B
Q2 25
$2.1B
$1.9B
Q1 25
$2.3B
$1.9B
Q4 24
$2.0B
Q3 24
$1.7B
$2.2B
Q2 24
$2.2B
Q1 24
$3.1B
Stockholders' Equity
CLMT
CLMT
STE
STE
Q4 25
$-732.7M
$7.2B
Q3 25
$-695.3M
$7.0B
Q2 25
$-1.0B
$7.0B
Q1 25
$-862.3M
$6.6B
Q4 24
$6.4B
Q3 24
$-672.2M
$6.6B
Q2 24
$-566.4M
$6.4B
Q1 24
$6.3B
Total Assets
CLMT
CLMT
STE
STE
Q4 25
$2.7B
$10.6B
Q3 25
$2.7B
$10.4B
Q2 25
$2.8B
$10.4B
Q1 25
$2.8B
$10.1B
Q4 24
$10.0B
Q3 24
$2.6B
$10.2B
Q2 24
$100
$10.1B
Q1 24
$11.1B
Debt / Equity
CLMT
CLMT
STE
STE
Q4 25
0.27×
Q3 25
0.27×
Q2 25
0.27×
Q1 25
0.29×
Q4 24
0.32×
Q3 24
0.33×
Q2 24
0.35×
Q1 24
0.50×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CLMT
CLMT
STE
STE
Operating Cash FlowLast quarter
$116.5M
$298.2M
Free Cash FlowOCF − Capex
$103.8M
$199.5M
FCF MarginFCF / Revenue
10.0%
13.3%
Capex IntensityCapex / Revenue
1.2%
6.6%
Cash ConversionOCF / Net Profit
1.55×
TTM Free Cash FlowTrailing 4 quarters
$56.6M
$917.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CLMT
CLMT
STE
STE
Q4 25
$116.5M
$298.2M
Q3 25
$23.5M
$287.8M
Q2 25
$-1.8M
$420.0M
Q1 25
$-29.3M
$260.8M
Q4 24
$332.8M
Q3 24
$-15.5M
$250.7M
Q2 24
$303.7M
Q1 24
$254.8M
Free Cash Flow
CLMT
CLMT
STE
STE
Q4 25
$103.8M
$199.5M
Q3 25
$15.1M
$201.3M
Q2 25
$-15.4M
$326.4M
Q1 25
$-46.9M
$189.9M
Q4 24
$243.6M
Q3 24
$-32.2M
$148.8M
Q2 24
$195.7M
Q1 24
$163.3M
FCF Margin
CLMT
CLMT
STE
STE
Q4 25
10.0%
13.3%
Q3 25
1.4%
13.8%
Q2 25
-1.5%
23.5%
Q1 25
-4.7%
12.8%
Q4 24
17.8%
Q3 24
-2.9%
11.2%
Q2 24
15.3%
Q1 24
14.6%
Capex Intensity
CLMT
CLMT
STE
STE
Q4 25
1.2%
6.6%
Q3 25
0.8%
5.9%
Q2 25
1.3%
6.7%
Q1 25
1.8%
4.8%
Q4 24
6.5%
Q3 24
1.5%
7.7%
Q2 24
2.2%
8.4%
Q1 24
8.2%
Cash Conversion
CLMT
CLMT
STE
STE
Q4 25
1.55×
Q3 25
0.07×
1.50×
Q2 25
2.37×
Q1 25
1.79×
Q4 24
1.92×
Q3 24
1.67×
Q2 24
2.09×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CLMT
CLMT

Specialty Products And Solutions$675.9M65%
Montana Renewables$294.2M28%
Performance Brands$68.5M7%

STE
STE

Servicerevenues$404.7M27%
Consumablerevenues$387.1M26%
Applied Sterilization Technologies$286.6M19%
Capitalequipmentrevenues$272.1M18%
Life Science$145.8M10%

Related Comparisons